Sermo
Access Breaking Physician Insights: Sermo’s Real Time Global Barometer
Access Breaking Physician Insights: Sermo’s Real Time Global Barometer
Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson’s team delved into the National…
Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions…
Highlights monthly webcast presentations for CE credit by FDA scientists from across agency on their cutting-edge scientific research
Let’s lace up and unlock $100,000 for medical research. 2,500 healthcare professionals run (or walk). We donate.
Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association’s (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in…
APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), ARCHES trial, enzalutamide, Delta-like ligand 3 (DLL3), LuPSMA.
Nonsense-mediated RNA decay, or NMD, is an evolutionarily conserved molecular mechanism in which potentially defective messenger RNAs, or mRNAs (genetic material that instructs the body…
Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as…
Sam Chang and Siamak (Sia) Daneshmand discuss the ABLE-41 trial, focusing on the real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial’s design…
CVS Health is lowering its guidance for the year after a first-quarter miss on both profit and revenue. | The company posted $1.1 billion in…